# Clinical Trials Data ALK - Document 22

# Study to Evaluate Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients

## Clinical Trial: https://clinicaltrials.gov/study/NCT02041468

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Patients with histologically confirmed locally advanced or metastatic NSCLC\n\* Presence of the ALK-fusion oncogene (ALK+) as determined using a validated testing platform\n\* Measurable disease according to RECIST v. 1.1\n\* Planned or ongoing treatment with crizotinib\n\* Signed and dated IRB-approved informed consent document\n\* Ability to read and understand English or French\n\* 18 years of age or older\n\nExclusion Criteria:\n\n\* Acquired immunodeficiency syndrome (AIDS-related illnesses) or known HIV disease.\n\* Unwilling to provide consent for genetic studies of the tumor, whole blood, or plasma specimens.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) found positive for ALK mutation from participating hospitals in Quebec.",

Question:  
Based on the following clinical trial information, would a patient with a ALK gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided clinical trial information, a patient with an ALK gene mutation would be eligible for the clinical trial. The inclusion criteria specifically mention the requirement for the presence of the ALK-fusion oncogene (ALK+), which indicates that the trial is targeting patients with this mutation. Additionally, the study is focused on patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), and the patient must meet other criteria such as planned or ongoing treatment with crizotinib and being 18 years or older. Assuming the patient meets all the other inclusion and exclusion criteria, they would be eligible to participate in the trial.